• Clasto-Lactacystin β-lactone: Evidence and Limits

  2026-10-11

  Clasto-Lactacystin β-lactone is described by APExBIO as a cell-permeable, irreversible proteasome inhibitor, but the supplied evidence does not establish that this product was used in Liu et al.’s study of viral RIPK3 degradation. That primary study supports a viral mechanism linking SCF machinery, RIPK3 loss, necroptosis, inflammation and pathogenesis, while leaving important limits around model systems, pharmacological specificity and applicability to human disease.

• HLTP1, JNK Phosphorylation, and Liver Injury

  2026-10-10

  A 2026 World Journal of Gastroenterology study identified human liver transplantation peptide 1 (HLTP1) through peptidomic analysis of clinical liver-transplant samples and evaluated its protective activity in hepatic ischemia-reperfusion injury. The findings connect HLTP1 with reduced Jun N-terminal kinase phosphorylation and hepatocyte apoptosis, while the available evidence remains preclinical and requires independent validation.

• HNF4A-AS1 and Sorafenib Resistance in HCC

  2026-10-09

  A 2024 Theranostics study links reduced HNF4A-AS1 to sorafenib resistance in hepatocellular carcinoma through METTL3- and YTHDF3-associated regulation of DECR1, PUFA abundance, and ferroptosis. The findings provide a preclinical lipid-metabolism framework for treatment resistance, while leaving clinical validation and glucose-uptake phenotyping open.

• Dual-Readout mRNA Delivery: Evidence and Limits

  2026-10-09

  This overview examines how Cy5-labeled reporter mRNA can conceptually separate cellular uptake from protein expression, while comparing supplier claims with recent β-cell delivery findings and outlining important evidence gaps.

• Magneto-Piezoelectric Scaffolds for Infectious Bone Repair

  2026-10-08

  Wu et al. developed a dual-responsive, 3D-printed scaffold designed to combine biofilm disruption with immune-regulated bone regeneration. The study links Icam1+ macrophage oxidative phosphorylation to JAK2–STAT3 and MAPK–JNK signaling, providing a mechanistic framework for evaluating multifunctional biomaterials in infectious bone defects.

• Balsalazide in Ulcerative Colitis: Evidence and Limits

  2026-10-08

  The 2009 review by Wiggins and Rajapakse evaluates balsalazide as a colon-targeted 5-aminosalicylate prodrug for mild-to-moderate active ulcerative colitis. Its central finding is that bacterial azoreduction can support colonic delivery of 5-ASA, with clinical evidence suggesting effective remission induction, favorable tolerability, and a possible speed advantage over mesalamine.

• Necrostatin 2: Reading Cell Death Evidence

  2026-10-07

  Necrostatin 2 (Nec-2) can help frame necroptosis inhibition research, but its value depends on separating target claims from direct evidence. This article connects the compound’s reported properties with a TMEM16F–Kupffer cell study to clarify what membrane injury, inflammation, and programmed necrotic cell death can—and cannot—show.

• C34: A Mechanistic Lens on TLR4 Research

  2026-10-06

  C34 is a selective TLR4 inhibitor for interpreting inflammatory signaling across macrophage, enterocyte, and neuroinflammation models. This article distinguishes pathway association from causal evidence and explains how C34 can serve as a mechanistic comparator in translational research.

• Cy3 TSA Fluorescence System Kit for Epigenetic Mapping

  2026-10-06

  The Cy3 TSA Fluorescence System Kit can make weak spatial signals more interpretable in fixed-cell and tissue research. This article examines how tyramide amplification may support studies of TRIM66-dependent olfactory receptor regulation while defining the limits of fluorescence-based evidence.

• AP20187 and Translational Cell Control

  2026-10-05

  AP20187 is a chemical inducer of dimerization that connects engineered protein proximity with conditional signaling. This thought-leadership analysis examines how it may support mechanistic research and translational decision-making while distinguishing vendor-reported capabilities from evidence established in a recent chronic intermittent hypoxia study.

• IPR-803: From uPAR Binding to Evidence

  2026-10-05

  IPR-803 is a urokinase receptor inhibitor whose value extends beyond simple pathway blockade. This evidence-focused analysis separates interface pharmacology from cellular and animal-model findings, clarifying what the compound can—and cannot—establish in cancer research.

• HLTP1 Targets JNK in Hepatic Ischemia–Reperfusion Injury

  2026-10-04

  A 2026 World Journal of Gastroenterology study used human liver-transplant peptidomics to identify human liver transplantation peptide 1 (HLTP1), a candidate hepatoprotective peptide. Across a murine injury model and AML12 cell experiments, the authors linked HLTP1 protection to reduced JNK phosphorylation and apoptosis, while rescue with JNK activation supported pathway involvement.

• IR-820 and New Indocyanine Green: Evidence Overview

  2026-10-03

  IR-820, also called New Indocyanine Green, is presented by APExBIO as a near-infrared research dye for vascular and tumor imaging. The supplied peer-reviewed study provides related but not direct evidence: it investigated indocyanine green in a glutathione-responsive MOF nanoparticle for photothermal and immunotherapy in melanoma. This overview separates vendor-reported properties from published findings, explains possible research applications, and defines the limits of translating engineered ICG nanomedicine results to IR-820.

• Dynasore in Endocytosis and Cancer Cell Assays

  2026-10-02

  Explore how Dynasore can convert dynamin-dependent membrane trafficking into a causal assay variable, with a focused framework for studying bacterial extracellular vesicles, colorectal cancer, and endocytosis research.

• Pseudo-UTP: Designing Better Translational mRNA

  2026-10-01

  Pseudouridine chemistry is becoming a strategic design variable in RNA therapeutics rather than a downstream formulation detail. This thought-leadership analysis connects Pseudo-UTP-enabled transcription with RNA performance, lipid nanoparticle delivery, antigen architecture, and translational decision-making.

7763 records 1/518 page Next 12345 下5页 Last page